Search

Your search keyword '"Sokol, Juraj"' showing total 203 results
Start Over Author "Sokol, Juraj" Publication Year Range Last 50 years
203 results on '"Sokol, Juraj"'

4. Platelet miRNA Expression in Patients with Sticky Platelet Syndrome

Author

Belakova Kristina Maria, Zolkova Jana, Vadelova Lubica, Skerenova Maria, Ivankova Jela, Lisa Lenka, Sokol Juraj, and Stasko Jan

Subjects
sticky platelet syndrome, mirna, expression, Medicine
Abstract

Sticky platelet syndrome (SPS) is a disorder with familial occurrence and autosomal dominant trait characterized by platelet hyperaggregability in response to a low concentration of adenosine diphosphate (ADP) and/or epinephrine (EPI). The etiology of SPS may be associated with platelet microRNAs (miRNAs), which are considered as potential biomarkers of platelet function and antiplatelet therapy. We were monitoring the expression of platelet miRNAs in patients with laboratory diagnosed SPS and healthy controls. We have found a statistically significant increased expression of both miR-423-5p and miR-338-3p as well as a statistically significant decreased expression of miR-425-5p between the group of patients with diagnosed SPS type II and the group of healthy controls, which seems to be an interesting issue for a further research.

Published
2023
Full Text
View/download PDF

7. Kardiotoxická liečba v onkohematológii.

Author

Sokol, Juraj, Nehaj, František, Chudej, Juraj, Lisá, Lenka, Lineková, Ľudmila, Jusko, Richard, Kecskés, Ivan, and Plameňová, Ivana

Subjects
*CARDIAC hypertrophy, *BRUTON tyrosine kinase, *CARDIOTOXICITY, *ATRIAL fibrillation, *CELLULAR signal transduction
Abstract

Chemotherapy and targeted therapy have significantly improved the prognosis of oncohaematological patients. Antineoplastic treatment can cause adverse cardiovascular effects known as cardiotoxicity, which requires modification, interruption or withdrawal of life-saving drugs. The onset of cardiotoxicity may depend on the class, dose, route, and duration of anticancer drug administration and individual risk factors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability. At the same time, new targeted molecules work by interfering with signalling pathways that are important for tumour cells and cardiomyocytes. For example, Bruton tyrosine kinase (BTK) inhibitors interfere with phosphatidylinositol-3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various proteins. Off-target effects of BTK inhibitors are associated with an increased incidence of atrial fibrillation. This review summarises current knowledge about the cardiotoxic effects of targeted therapies used in haematology. Fig. 2, Tab. 3, Ref. 44, on-line full text (Free, PDF) www.cardiology.sk [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Role of Platelets in Rheumatic Chronic Autoimmune Inflammatory Diseases.

Author

Péč, Martin Jozef, Jurica, Jakub, Péčová, Monika, Benko, Jakub, Sokol, Juraj, Bolek, Tomáš, Samec, Marek, Hurtová, Tatiana, Galajda, Peter, Samoš, Matej, and Mokáň, Marián

Subjects
AUTOIMMUNE diseases, BLOOD platelets, SYSTEMIC lupus erythematosus, INFLAMMATION, THERAPEUTICS
Abstract

Platelets are essential in maintaining blood homeostasis and regulating several inflammatory processes. They constantly interact with immune cells, have immunoregulatory functions, and can affect, through immunologically active substances, endothelium, leukocytes, and other immune response components. In reverse, inflammatory and immune processes can activate platelets, which might be significant in autoimmune disease progression and arising complications. Thus, considering this interplay, targeting platelet activity may represent a new approach to treatment of autoimmune diseases. This review aims to highlight the role of platelets in the pathogenic mechanisms of the most frequent chronic autoimmune inflammatory diseases to identify gaps in current knowledge and to provide potential new targets for medical interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Evaluating Thromboprophylaxis Strategies for High-Risk Pregnancy: A Current Perspective.

Author

Stančiaková, Lucia, Brisudová, Kristína, Škorňová, Ingrid, Bolek, Tomáš, Samoš, Matej, Biringer, Kamil, Staško, Ján, and Sokol, Juraj

Subjects
HIGH-risk pregnancy, PREGNANT women, CESAREAN section, THROMBOEMBOLISM, FAMILY history (Medicine), SCIENCE databases
Abstract

Venous thromboembolism (VTE) represents one of the leading causes of death during pregnancy. The greatest risk for it is the presence of medical or family history of VTE, stillbirth, cesarean section and selected thrombophilia. Appropriate thromboprophylaxis has the potential to decrease the risk of VTE in at-risk pregnant patients by 60–70%. Based on this, the authors reviewed the PubMed, Web of Science and Scopus databases to identify the possibilities of thromboprophylaxis in pregnant patients with a high risk of VTE. Moreover, they summarized its management in specific situations, such as cesarean delivery or neuraxial blockade. Currently, low-molecular-weight heparins (LMWH) are the preferred drugs for anticoagulant thromboprophylaxis in the course of pregnancy and postpartum due to easy administration and a lower rate of adverse events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Role of Platelets in Rheumatic Chronic Autoimmune Inflammatory Diseases

Author

Péč, Martin Jozef, additional, Jurica, Jakub, additional, Péčová, Monika, additional, Benko, Jakub, additional, Sokol, Juraj, additional, Bolek, Tomáš, additional, Samec, Marek, additional, Hurtová, Tatiana, additional, Galajda, Peter, additional, Samoš, Matej, additional, and Mokáň, Marián, additional

Published
2023
Full Text
View/download PDF

12. A Functional Assay for the Determination of Heparin-Induced Thrombocytopenia via Flow Cytometry

Author

Skornova, Ingrid, primary, Simurda, Tomas, additional, Stanciakova, Lucia, additional, Lauko, Viliam, additional, Holly, Pavol, additional, Samos, Matej, additional, Bolek, Tomas, additional, Schnierer, Martin, additional, Drotarova, Miroslava, additional, Belakova, Kristina Maria, additional, Sokol, Juraj, additional, Stasko, Jan, additional, Mokan, Marian, additional, Gumulec, Jaroslav, additional, and Chrastinova, Leona, additional

Published
2023
Full Text
View/download PDF

21. Multimer Analysis of Von Willebrand Factor in Von Willebrand Disease with a Hydrasys Semi-Automatic Analyzer—Single-Center Experience

Author

Skornova, Ingrid, primary, Simurda, Tomas, additional, Stasko, Jan, additional, Zolkova, Jana, additional, Sokol, Juraj, additional, Holly, Pavol, additional, Dobrotova, Miroslava, additional, Plamenova, Ivana, additional, Hudecek, Jan, additional, Brunclikova, Monika, additional, Stryckova, Alena, additional, and Kubisz, Peter, additional

Published
2021
Full Text
View/download PDF

23. Arteria lusoria - a rare cause of dysphagia or a common accidental finding?

Author

Péč, Martin Jozef, primary, Kučeríková, Monika, additional, Grilusová, Kristína, additional, Slobodníková, Veronika, additional, Strýčková, Alena, additional, Beliančinová, Monika, additional, Sokol, Juraj, additional, Samoš, Matej, additional, Galajda, Peter, additional, Zeleňák, Kamil, additional, and Mokáň, Marián, additional

Published
2021
Full Text
View/download PDF

41. Genetic Background of von Willebrand Disease: History, Current State, and Future Perspectives.

Author

Zolkova, Jana, Sokol, Juraj, Simurda, Tomas, Vadelova, Lubica, Snahnicanova, Zuzana, Loderer, Dusan, Dobrotova, Miroslava, Ivankova, Jela, Skornova, Ingrid, Lasabova, Zora, Kubisz, Peter, and Stasko, Jan

Subjects
*HISTORY of diseases, *VON Willebrand factor, *BLOOD coagulation factors, *GENETIC testing, *VON Willebrand disease, *NUCLEOTIDE sequencing
Abstract

Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 mutations and many disease-causing mechanisms have been described in the 35 years since the VWF gene was identified. Genetic testing in VWD patients is now available in many centers as a part of the VWD diagnostic algorithm. Molecular mechanisms leading to types 2 and 3 VWD are well characterized; thus, information from genetic analysis in these VWD types may be beneficial for their correct classification. However, the molecular basis of type 1 VWD is still not fully elucidated and most likely represents a multifactorial disorder reflecting a combined impact of environmental and genetic factors within and outside of VWF . Regarding sequencing methods, the previous gold-standard Sanger sequencing is gradually being replaced with next-generation sequencing methods that are more cost- and time-effective. Instead of gene-by-gene approaches, gene panels of genes for coagulation factors and related proteins have recently become a center of attention in patients with inherited bleeding disorders, especially because a high proportion of VWD patients, mainly those with low VWF plasma levels (type 1), appear to be free of mutations in VWF. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are accessible in a very limited number of laboratories. Results from these studies have presented several genes other than VWF or ABO possibly affecting VWF levels, and such findings will need further validation studies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

45. Is Amanita phalloides poisoning still a problem?

Author

Neháj, František, primary, Krivuš, Juraj, additional, Mokáň, Michal, additional, Kubašková, Marianna, additional, Sokol, Juraj, additional, Galajda, Peter, additional, Kovář, František, additional, Péč, Martin, additional, and Mokáň, Marián, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results